BCL2 and acute myeloid leukemia: In AML, this LIC-specific dependency on OXPHOS can be specifically targeted using venetoclax (a BCL2 inhibitor), which suppresses both the TCA cycle and OXPHOS, probably through decreased amino acid uptake, which fuels the TCA cycle in AML LICs [11,12,22].